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Wan-Seob Cho1, Byeong-Cheol Kang2, Jong Kwon Lee3, Jayoung Jeong3, Jeong-Hwan Che2*†
and Seung Hyeok Seok4*†Abstract
Background: The in vivo kinetics of nanoparticles is an essential to understand the hazard of nanoparticles. Here,
the absorption, distribution, and excretion patterns of titanium dioxide (TiO2) and zinc oxide (ZnO) nanoparticles
following oral administration were evaluated.
Methods: Nanoparticles were orally administered to rats for 13 weeks (7 days/week). Samples of blood, tissues
(liver, kidneys, spleen, and brain), urine, and feces were obtained at necropsy. The level of Ti or Zn in each sample
was measured using inductively coupled plasma-mass spectrometry.
Results: TiO2 nanoparticles had extremely low absorption, while ZnO nanoparticles had higher absorption and a
clear dose-response curve. Tissue distribution data showed that TiO2 nanoparticles were not significantly increased
in sampled organs, even in the group receiving the highest dose (1041.5 mg/kg body weight). In contrast, Zn
concentrations in the liver and kidney were significantly increased compared with the vehicle control. ZnO
nanoparticles in the spleen and brain were minimally increased. Ti concentrations were not significantly increased
in the urine, while Zn levels were significantly increased in the urine, again with a clear dose-response curve. Very
high concentrations of Ti were detected in the feces, while much less Zn was detected in the feces.
Conclusions: Compared with TiO2 nanoparticles, ZnO nanoparticles demonstrated higher absorption and more
extensive organ distribution when administered orally. The higher absorption of ZnO than TiO2 nanoparticles might
be due to the higher dissolution rate in acidic gastric fluid, although more thorough studies are needed.
Keywords: TiO2, ZnO, Oral administration, Absorption, Distribution, ExcretionBackground
Nanomaterials have been developed for the food indus-
try for uses such as food storage, preventing microbial
growth, and as a nutritional ingredient [1,2]. Titanium
dioxide (TiO2) and zinc oxide (ZnO) have unique physi-
cochemical properties including a bright white color,
ability to block UV light, and antimicrobial activity.
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reproduction in any medium, provided the orcrystalline structures (anatase, rutile and brookite) and
have a high refractive index. TiO2 is widely used as a
pigment (paint, plastics, and paper), in personal care
products (sunscreen and toothpastes), and in food
(cream) [3]. The bright white color of micron-sized TiO2
might be more useful for some applications than
nanosized TiO2 because TiO2 becomes more transparent
as its particle size decreases. However, smaller TiO2 par-
ticles have higher UV-blocking properties, which can be
advantageous for food storage [4]. In addition, nanosized
TiO2 prevents microbial growth [5]. Because of these
properties, nanosized TiO2 might be popular in the food
industry with further technological developments. ZnO
is another commonly used particle with similar utility to
TiO2. In addition, ZnO is used for its antimicrobial. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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vitamins [6,7]. Compared with micron-sized ZnO,
nanosized ZnO might have better UV-blocking and anti-
microbial properties and higher bioavailability [8].
The increased use of these particles might increase the
possibility of human exposure through various routes such
as inhalation, ingestion, and skin contact. In addition to uses
for humans, nanomaterials are used with livestock and in
the environment. TiO2 nanoparticles are generally consid-
ered to have low toxicity regardless of their size and crystal-
linity [9]. However, recent in vitro studies have reported
that TiO2 nanoparticles are genotoxic through the produc-
tion of reactive oxygen species [10,11], although in vitro
studies have limited predictive value for in vivo situations.
In contrast to TiO2 nanoparticles, ZnO nanoparticles are
well known to have high toxicity. One of the mechanisms
of this toxicity is their ionization in biological fluids [12].
Combined with toxicity data, kinetics data can provide
the actual concentration of nanoparticles as they interact
with biological systems. However, compared with other
routes of administration, kinetics data following the oral
administration of nanoparticles is limited. Humans have
a higher chance of being exposed to TiO2 and ZnO
nanoparticles in food-related products than other
nanoparticles. Therefore, further evaluation of the tissue
distribution and absorption of these nanoparticles fol-
lowing oral administration is needed to provide valuable
information for assessing the risk of these nanoparticles.
We selected TiO2 and ZnO to evaluate nanoparticleFigure 1 SEM and TEM of TiO2 and ZnO nanoparticles. SEM (A) and TE
TEM (D) images of ZnO nanoparticles show hexagonal shape.absorption, tissue distribution, and excretion following
13 weeks of repeated oral administration.Results
Physicochemical characterization of nanoparticles
TiO2 nanoparticles were spherical and ZnO nanoparticles
were hexagonal (Figure 1). Table 1 summarizes the physi-
cochemical properties of the TiO2 and ZnO nanoparticles.
The primary sizes of TiO2 nanoparticles provided by the
manufacturer were similar to those measured by scanning
electron microscopy (SEM) and dynamic light scattering
(DLS), while ZnO nanoparticles sizes differed significantly
by the two measurement type. The hydrodynamic size of
the ZnO nanoparticles suggested that ZnO formed small
aggregates when dispersed in distilled water (DW). TiO2
nanoparticles had sizes similar to the primary particle size.
No particles showed endotoxin contamination. The zeta
potential of the TiO2 nanoparticles was 54.4 ± 0.7 mV for
pH 2 and 7.9 ± 2.7 mV for pH 8. The zeta potential of
ZnO was more negative than TiO2, at 11.7 ± 0.8 mV for
pH 2 and -25.1 ± 2.6 mV for pH 8.Durability of nanoparticles under biological conditions
TiO2 nanoparticles showed minimal dissolution in both
acidic gastric fluid (AGF) and pH 7.4 conditions (Figure 2A).
However, ZnO nanoparticles dissolved in AGF within five
minutes. In basic conditions, ZnO showed minimal dissol-
ution after monitoring for up to 24 h. This dissolutionM (B) images of TiO2 nanoparticles show spherical shape. SEM (C) and
Table 1 Physicochemical characterization of metal oxide nanoparticles
Particles Crystallinity Primary size (nm) measured by Hydrodynamic
size (nm)a
Surface
area (m2/g)b
Endotoxin
(pg/ml)cManufacturer SEM
TiO2 Anatase 80: 20 Rutile 21 26.4 ± 6.1 37.8 ± 0.4 50±15 N.D.
ZnO Hexagonal 40 89.3 ± 44.7 201.8 ± 17.2 60±10 N.D.
ND not detectable. SEM scanning electron microscopy.
aNanoparticles were dispersed in DW and measured by a dynamic light scattering method.
bSpecific surface area by the Brunauer-Emmett-Teller method was provided by the manufacturer.
cLevels of endotoxin were measured using an Endpoint Chromogenic Limulus Amebocyte Lysate assay (Cambrex, MD, USA).
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mass spectrometry (ICP-MS) (Figure 2B).
Body weight changes
When nanoparticles were administered for consecutive
13-week to female Sprague-Dawley rats, the body weight
of given a high dose of ZnO nanoparticles was signifi-
cantly lower than animals given in the vehicle control
(Additional file 1: Tables S1–S4). However, other ZnO-
treatment groups and the TiO2 nanoparticle-treatment
groups showed no significant changes compared with
the vehicle-control group.
Absorption of nanoparticles
The concentrations of Zn in the blood of the ZnO-
treatment groups demonstrated a clear dose-response re-
lationship (Figure 3). However, the concentrations of Ti in
the male TiO2-treatment groups showed a less steep slope
in the dose-response relationship. Female rats treated with
TiO2 showed no dose-response relationship for blood
concentration. The Zn blood concentration in the ZnO-
treatment groups was almost 10-fold higher than the Ti
concentration in the TiO2-treatment groups.
Distribution of nanoparticles
The distribution patterns of Ti and Zn in the liver, spleen,
kidney, and brain after 13 weeks of repeated oral adminis-
tration of TiO2 or ZnO nanoparticles were measured using
ICP-MS. Ti concentrations in the TiO2-treatment groupsFigure 2 Dissolution pattern of nanoparticles in the acidic gastric flui
incubated with AGF or DW for up to 24 h. (A) Image taken 5 min after incu
using an ICP-MS at 24 h after incubation.showed no significant increase in the sampled organs
compared with the vehicle control group (Figure 4 and
Additional file 2: Figure S1). The Zn concentration in the
liver and kidney showed a significant increase in the
highest dose group with a positive, dose-related trend
(Figure 5 and Additional file 2: Figure S2). In addition, the
concentration of Zn in liver and kidney was much higher
than in the spleen and brain. In spleen and brain tissue, the
Zn concentration showed no dose-related response com-
pared with the vehicle control, even in the high-dose group.
Excretion of nanoparticles
The urine concentration of Ti in the TiO2-treatment
groups showed no significant differences compared with
the control group, which was consistent with the tissue
distribution patterns (Figure 6A). In contrast, the con-
centration of Zn in the urine of ZnO-treatment groups
was significantly increased in the middle- and high-dose
groups and showed positive trend dose-responses
(Figure 6C). Ti or Zn concentrations in the feces were
very high compared to concentrations in the urine or
tissues, with clear dose responses. These results sug-
gested that most of the nanoparticles were not absorbed
from the gastrointestinal lumen (Figures 6B and 6D).
Discussion
TiO2 and ZnO particles are widely used as ingredients
and food supplements [3,6,7]. As nanotechnology de-
velops, these traditional materials have also been appliedd. AGF, pH 1.5; basic condition, DW, pH 7.4. Nanoparticles were
bation using a digital camera. (B) Percentage of dissolution measured
Figure 3 Systemic absorption of nanoparticles from the
gastrointestinal tract after 13 weeks of repeated oral
treatment. Ti concentration in whole blood (A) showed about a 10-
fold lower absorption than Zn concentration in whole blood (B) in
both sexes. Values are mean ± S.D. and n = 11. Significance versus
vehicle control: * p < 0.05.
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with biological systems through different mechanisms of
action than bulk chemicals [13]. Nanoparticles are consid-
ered to be more highly absorbed into the respiratory, skin,
and gastrointestinal systems than micron-sized particles
because of their unique physicochemical properties, such
as their size and surface modifications [14]. For example,
instillation of 5 nm fluorescent nanoparticles shows faster
translocation to other organs than 27 nm nanoparticles
[15]. In addition, a recent study showed that onlynanoparticles were translocated into the circulation sys-
tem when administered into the lung; their absorption rate
varied, depending on their surface properties [16]. The up-
take of particles into skin cells was observed to be size
dependent [17]. When different sizes of polystyrene parti-
cles were administered orally to rats, the absorption of
50–100 nm polystyrene nanoparticles was about 250-fold
higher than absorption of larger microparticles (500 nm,
1, and 10 μm) [18,19]. Oral administration of different
sizes of colloidal gold particles to mice showed size-
dependent absorption [20]. Regarding surface modifica-
tion, positively charged particles show better absorption
than neutral or negatively charged particles [21]. However,
in a recent study using gold nanoparticles, negatively
charged particles showed higher absorption rates than
positively charged particles [22]. Therefore, no general rule
can be made about absorption from these results and fur-
ther studies are needed on the impact of surface modifica-
tion on gastrointestinal absorption. Studying the kinetics
of nanoparticles is an important issue in nanotechnology.
Compared with inhalation or skin exposure, the oral in-
take of nanoparticles in food-related settings has the po-
tential for wide exposure of the public to higher doses and
more frequent ingestion [1,2]. This study focused on the
kinetics of the nano-particulate forms of TiO2 and ZnO as
representative food-related nanomaterials.
Both particle types showed very low absorption al-
though the exact absorption rate could not be calculated.
The concentration of Ti in the blood samples of rats
treated with TiO2 for 13 weeks was 0.4–0.5 μg/g and the
differences between the values of the control and high-
dose groups were less than 0.1 μg/g. Considering that
the dose for the high-dose group was 1041.5 mg/kg body
weight, TiO2 nanoparticles might have an extremely low
absorption rate, although additional experiments are
needed to confirm this. In contrast, the Zn concentra-
tion in the blood of rats in the ZnO-treatment groups
showed an almost 10-fold higher dose and a steeper
dose-response curve than values for animals in the Ti
groups. The higher concentration of Zn in blood com-
pared to Ti might be because of the biopersistence of
nanoparticles. TiO2 and ZnO nanoparticles have differ-
ent durability under acidic conditions, although both are
minimally destructive in basic or physiological condi-
tions. In our previous study, ZnO nanoparticles showed
rapid dissolution in acidic conditions (pH 5.5) [12,23].
Because the pH of the gastric fluid is between 1.5 and
2.0, ZnO nanoparticles administered orally must dissolve
in the stomach, with Zn ions then absorbed to enter into
systemic circulation. In contrast, the low absorption rate
of TiO2 might be because of their low solubility. The
low absorption after oral administration of nanoparticles
is consistent with the micron-sized biocompatible TiO2
particles [24]. Low absorption would be favorable from a
Figure 4 Concentration of Ti in tissues after 13 weeks of consecutive oral administration of TiO2 nanoparticles. The concentrations of Ti in
the liver (A), spleen (B), kidney (C), and brain (D) were evaluated using an ICP-MS. Values are mean ± S.D. and n = 11. Significance versus vehicle
control: * p < 0.05.
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of nanoparticles such as in food preparation, handling, stor-
age, and prevention of microbial growth. However, even
with marginal absorption, some absorbed nanoparticles
might pose a risk based on their toxic potential.
TiO2 distribution to the liver, spleen, kidney, and brain
was also minimal. No dose-response relationship was
seen, meaning that the TiO2 particles were not signifi-
cantly distributed. This low distribution was due to the
minimal absorption rate. This result was in contrast with
a previous study that observed systemic translocation of
TiO2 nanoparticles through the gastrointestinal tract [3].
Therefore, further studies and advanced methods to de-
tect nanoparticles in the tissues are warranted. However,
ZnO nanoparticles showed significant levels of Zn in the
tested organs, particularly in the liver and kidney, with
steep dose-response curves. In a previous study, orally
administered ZnO nanoparticles were mainly distribu-
ted to the liver and kidney within 72 h followingadministration [25,26]. When two different sizes of ZnO
were administered, the particle size and gender of ani-
mals did not influence the tissue distribution pattern
[25]. In addition, orally administered zinc-65 was mainly
distributed in the liver, muscle, lung, kidneys, and bone
[27].
Data on the excretion of the nanoparticles were consist-
ent with the absorption and distribution patterns. The Ti
concentration in urine showed no significant differences
from the controls, while the Zn concentration in urine
was significantly higher than the vehicle controls, with
clear dose-responses. ZnO nanoparticles administered or-
ally are excreted via the urine [25]. The main routes of
elimination of nanoparticles are urine/kidney and bile/
liver. Renal excretion was confirmed in several studies
using a multi-walled carbon nanotube [28] and quantum
dots [29]. However, studies using quantum dots [30,31]
and gold nanoparticles [32] showed long-term accumula-
tion in the organs and no or minimal excretion via urine.
Figure 5 Concentration of Zn in tissues after 13 weeks of consecutive oral administration of ZnO nanoparticles. The concentrations of
Zn in the liver (A), spleen (B), kidney (C), and brain (D) were evaluated using an ICP-MS. Values are mean ± S.D. and n = 11. Significance versus
vehicle control: * p < 0.05.
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limited and further studies are warranted.
Conclusions
Zinc concentrations in blood, organs, and urine were
higher than concentrations of titanium when nanoparticles
were administered orally for 13 weeks. The kinetics of
nanoparticles via oral administration might be influenced
by interactions between the physicochemical properties of
nanoparticles and the biological milieu with which they
come into contact. The low absorption of TiO2 and ZnO
nanoparticles might be favorable, especially for non-
nutritional applications. More thorough instigations re-
garding the impact of physicochemical properties on the
kinetics of nanoparticles are warranted.
Methods
Nanoparticles and physicochemical characterization
Powder-form TiO2 nanoparticles were obtained from
ABC Nanotech Co., Ltd. (Daejeon, Korea). Well-dispersedZnO nanoparticles at 20 wt% in distilled water (DW)
were obtained from Nanostructured and Amorphous
Materials, Inc. (TX, USA). Primary particle sizes and
morphology were measured using scanning electron mi-
croscopy (S-3500 N, Hitachi Science Systems, Ltd., Japan)
and transmission electron microscopy (LEO-912AB
Omega, LEO, Japan). The hydrodynamic size and zeta po-
tential of nanoparticles in DW were measured using a
DelsaNano (Beckman Coulter, Inc., CA, USA) according
to the manufacturer’s instructions. Briefly, the optimal
concentration of TiO2 and ZnO for measurement was
screened by serial dilution under following conditions:
temperature 25°C, refractive index 1.33, scattering angle
165°, laser wavelength 632.8 nm. The zeta potential of
nanoparticles was measured under acidic conditions
(pH 2.0) to simulate acidic gastric conditions, and under
basic conditions (pH 8.0) to simulate the small intestine.
Levels of endotoxin contamination were measured using
an Endpoint Chromogenic Limulus Amebocyte Lysate
assay (Cambrex, MD, USA).
Figure 6 Excretion of nanoparticles after 13 weeks of consecutive oral administration. The concentrations of Ti in urine (A) and feces (C)
were measured using an ICP-MS for TiO2 treatment groups. The concentrations of Zn in urine (B) and feces (D) were measured using an ICP-MS
for ZnO treatment groups. Values are mean ± S.D. and n = 11. Significance versus vehicle control: * p < 0.05.
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TiO2 and ZnO nanoparticles were incubated with acidic
gastric fluid (AGF, pH 1.5–2.0) or under basic conditions
(pH 7.4). AGF was prepared according to a previously
described method [33]. Briefly, 2.0 g NaCl (Sigma-
Aldrich, St. Louis Mo. USA) and 3.2 g pepsin (Sigma-
Aldrich) were dissolved in 1 L of DW and the pH was
adjusted to 1.5 using 2 N HCl (Sigma-Aldrich). DW at
pH 7.4 was used for the basic solution. Nanoparticles at
5 mg/mL were incubated in solution for up to 24 h. The
degree of ionization was evaluated at 24 h post-
incubation using inductively coupled plasma-mass spec-
trometry (ICP-MS). Briefly, at 24 h after incubation in
solution, nanoparticle-free supernatants were collec-
ted by three rounds of centrifugation at 15000 × g for
30 min. The concentrations of zinc or titanium were
measured using ICP-MS (X7; Thermo Elemental,
Winsford, UK) as previously described method [34].
Gross images were taken using a digital camera (Nikon
Corp., Tokyo, Japan).Animal handling and protocols
Six-week-old specific-pathogen free Sprague-Dawley rats
were obtained from OrientBio Ltd. (Seongnam, Korea)
and acclimated for seven days after arrival at the study
facility. Rodents were housed in an animal room at a
controlled temperature (21–24ºC), humidity (45–60%),
and light cycle (12 h light/dark). Autoclaved water and
gamma-irradiated rodent diets (LabDiet 5002, PMI
nutrition, Richmond, USA) were provided ad libitum.
The concentration of zinc in the diet was 74 ± 7.1 ppm
as provided by the manufacturer (PMI Nutrition,
Richmond, USA) and was not detectable in water provi-
ded by the Office of Waterworks (Seoul Metropolitan
Government, Seoul, Korea). The concentrations of titan-
ium in the diet and water were not known. All animal
experiments were performed according to the Orga-
nization for Economic Co-operation and Development
test guideline (TG 408) and the Good Laboratory Prac-
tices for toxicity test guidance (Notification No. 2005-60,
Oct. 21, 2005) issued by the Korea Food and Drug
Cho et al. Particle and Fibre Toxicology 2013, 10:9 Page 8 of 9
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proved by the Animal Care and Use Committee of Seoul
National University Hospital, Korea.
Dose-range finding study for 13 weeks of repeated oral
nanoparticle administration
A single-dose acute toxicity study and a 14-day repeated
toxicity study of the oral route were performed. For the
14-day study, TiO2 was administered orally at 520.8,
1041.5, and 2083 mg/kg/day, and ZnO was administered
at 536.8, 1073.5, and 2147 mg/kg/day. Survival, clinical
signs, body weight change, hematological change, serum
biochemical change, organ weight, and necropsy findings
were evaluated for MTD endpoints. There were no
treatment-related findings in the TiO2 study; the highest
dose over 13 weeks was selected as 1041.5 mg/kg/day
for studying long-term exposure. For ZnO, clinical signs
(erection of fur, depression, abdominal inflation, and
diarrhea) and a more than 10% reduction of body weight
were observed at doses over 1073.5 mg/kg in both sexes.
Several hematological parameters and the level of alka-
line phosphatase were significantly differed than in the
vehicle control (data not shown). Based on these data,
the maximum tolerated dose (MTD) was determined to
be 1041.5 for TiO2 and 536.8 for ZnO nanoparticles.
13-week repeated oral administration of nanoparticles
Eleven rats were assigned to each of four treatment
groups: vehicle control (DW), ZnO nanoparticles at 134.2,
268.4, and 536.8 mg/kg/day, and TiO2 nanoparticles at
260.4, 520.8, and 1041.5 mg/kg/day. All nanoparticles
were suspended in DW at each working concentration
and orally administered at 10 ml/kg body weight
according to the Handbook of Toxicology, second edition
[35]. Administration volume was adjusted based on body
weight measured each week. Each group was treated
with same concentration of nanoparticles for the entire
13 weeks. Oral administration was done 7 days per week
without any anesthesia or starvation. Animals were
weighed weekly and observed daily for clinical signs and
mortality. Animals were sacrificed and dissected one day
after final gavage.
Absorption, distribution, and excretion of nanoparticles
Blood was taken via the abdominal vein at necropsy
followed by isoflurane euthanization. To evaluate tissue
distribution, tissue samples from the liver, spleen, kidney,
and brain were obtained and weighed. Nanoparticles ex-
cretion was tested in urine and feces. To collect urine and
feces, five animals from each group were randomly
assigned to a metabolic cage immediately after gavage, and
urine and feces samples were collected for 24 h. All sam-
ples were analyzed for elemental zinc and titanium to rep-
resent ZnO and TiO2 concentrations. ICP-MS was usedto analyze zinc and titanium concentrations in samples as
previously described [34]. The detection limit of ICP-MS
was 0.1–1 ng/L for Ti and 0.1–10 ng/L for Zn.
Statistical analysis
ICP-MS data were analyzed using one-way ANOVA
(JMP ver. 4.0, NC, USA). Animal data were analyzed
using TDMS ver 4.0 (KFDA, Osong, Korea). When sta-
tistically significant differences were indicated (p < 0.05),
a Dunnett’s t-test was employed for comparisons be-
tween the control and treatment groups.
Additional files
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